Introduction: Inflammatory skin reactions are the most common issue in Cetuximab-treated patients. Many evidences show the correlation with NB-UVB exposure, but the mechanisms are not completely understood. The aim of this study is the evaluation of the effects of NB-UVB exposure on inflammatory cytokines modulation during EGFR immunotherapy. Materials and methods: Human immortalized keratinocytes, HaCaT cells, were treated with 10 g/ml of Cetuximab for 24 hrs and NB-UVB exposed. Viability, ROS production and pro-inflammatory cytokines geneexpression and release were assessed. An additional, in vivo evaluation of Minimal Erythema Dose in Cetuximabtreated patients was performed. Results: NB-UVB exposure activates the inflammatory skin response in HaCaT cells, inducing the overexpression of pro-inflammatory mediators. Reduced cells viability, ROS production and expression and release of selected cytokines after Cetuximab-treatment. The co-treatment, with NB-UVB and Cetuximab, show the recovery with baseline conditions. In vivo evaluation underline that patient’s skin reactions are not changed after NB-UVB exposure. Conclusion: In conclusion, NB-UVB doesn't exacerbate papulopustular reactions developed during anti-EGFR treatment, both in vivo and in vitro evaluations. A better understanding of this relationship, between NB-UVB exposure and dermatological side effects, could throw a new light on sun exposure limitation, improving Cetuximabtreated patients QoL and favoring therapeutic adherence.

Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure

Costantini E;C. D’Angelo;R. Muraro;M. De Tursi;C. Natoli;M. Auriemma;M. Di Nicola;P. Amerio;ReaLE M
2018-01-01

Abstract

Introduction: Inflammatory skin reactions are the most common issue in Cetuximab-treated patients. Many evidences show the correlation with NB-UVB exposure, but the mechanisms are not completely understood. The aim of this study is the evaluation of the effects of NB-UVB exposure on inflammatory cytokines modulation during EGFR immunotherapy. Materials and methods: Human immortalized keratinocytes, HaCaT cells, were treated with 10 g/ml of Cetuximab for 24 hrs and NB-UVB exposed. Viability, ROS production and pro-inflammatory cytokines geneexpression and release were assessed. An additional, in vivo evaluation of Minimal Erythema Dose in Cetuximabtreated patients was performed. Results: NB-UVB exposure activates the inflammatory skin response in HaCaT cells, inducing the overexpression of pro-inflammatory mediators. Reduced cells viability, ROS production and expression and release of selected cytokines after Cetuximab-treatment. The co-treatment, with NB-UVB and Cetuximab, show the recovery with baseline conditions. In vivo evaluation underline that patient’s skin reactions are not changed after NB-UVB exposure. Conclusion: In conclusion, NB-UVB doesn't exacerbate papulopustular reactions developed during anti-EGFR treatment, both in vivo and in vitro evaluations. A better understanding of this relationship, between NB-UVB exposure and dermatological side effects, could throw a new light on sun exposure limitation, improving Cetuximabtreated patients QoL and favoring therapeutic adherence.
File in questo prodotto:
File Dimensione Formato  
epidermal-growth-factor-immunotherapy-exploring-the-effects-of-nbuvb-exposure-2161-0681-1000348.pdf

accesso aperto

Tipologia: PDF editoriale
Dimensione 532.46 kB
Formato Adobe PDF
532.46 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/699451
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact